- Home
- APTO vs MYNZ Comparison
APTO vs MYNZ Comparison
Compare APTO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTO
- MYNZ
- Stock Information
- Founded
- APTO 1986
- MYNZ 2021
- Country
- APTO Canada
- MYNZ Germany
- Employees
- APTO N/A
- MYNZ N/A
- Industry
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- APTO Health Care
- MYNZ Health Care
- Exchange
- APTO Nasdaq
- MYNZ Nasdaq
- Market Cap
- APTO 13.2M
- MYNZ 11.2M
- IPO Year
- APTO N/A
- MYNZ 2021
- Fundamental
- Price
- APTO $0.21
- MYNZ $4.83
- Analyst Decision
- APTO Strong Buy
- MYNZ Hold
- Analyst Count
- APTO 3
- MYNZ 2
- Target Price
- APTO $4.33
- MYNZ N/A
- AVG Volume (30 Days)
- APTO 19.3M
- MYNZ 135.3K
- Earning Date
- APTO 11-08-2024
- MYNZ 10-21-2024
- Dividend Yield
- APTO N/A
- MYNZ N/A
- EPS Growth
- APTO N/A
- MYNZ N/A
- EPS
- APTO N/A
- MYNZ N/A
- Revenue
- APTO N/A
- MYNZ $917,203.00
- Revenue This Year
- APTO N/A
- MYNZ $21.95
- Revenue Next Year
- APTO N/A
- MYNZ $30.77
- P/E Ratio
- APTO N/A
- MYNZ N/A
- Revenue Growth
- APTO N/A
- MYNZ 16.23
- 52 Week Low
- APTO $0.13
- MYNZ $0.18
- 52 Week High
- APTO $2.30
- MYNZ $7.95
- Technical
- Relative Strength Index (RSI)
- APTO 45.54
- MYNZ 53.87
- Support Level
- APTO $0.21
- MYNZ $3.86
- Resistance Level
- APTO $0.25
- MYNZ $6.81
- Average True Range (ATR)
- APTO 0.02
- MYNZ 0.74
- MACD
- APTO 0.00
- MYNZ -0.09
- Stochastic Oscillator
- APTO 19.86
- MYNZ 32.88
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.